Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13
Zevra Therapeutics (NASDAQ: ZVRA) has announced its participation in the upcoming Guggenheim Securities Healthcare Innovation Conference. The company's President and CEO, Neil F. McFarlane, will engage in a fireside chat on Wednesday, November 13, 2024, at 4 p.m. ET. The event will be held virtually, and management will be available for one-on-one meetings with registered attendees. Interested parties can access the live webcast through the 'Events & Presentations' section on Zevra's investor relations website at investors.zevra.com.
Zevra Therapeutics (NASDAQ: ZVRA) ha annunciato la sua partecipazione al prossimo Guggenheim Securities Healthcare Innovation Conference. Il Presidente e CEO dell'azienda, Neil F. McFarlane, parteciperà a un incontro informale mercoledì 13 novembre 2024, alle ore 16:00 ET. L'evento si svolgerà virtualmente e la direzione sarà disponibile per incontri one-on-one con i partecipanti registrati. Le parti interessate possono accedere al webcast dal vivo attraverso la sezione 'Eventi e Presentazioni' sul sito delle relazioni con gli investitori di Zevra all'indirizzo investors.zevra.com.
Zevra Therapeutics (NASDAQ: ZVRA) ha anunciado su participación en la próxima Guggenheim Securities Healthcare Innovation Conference. El presidente y CEO de la compañía, Neil F. McFarlane, participará en una charla informal el miércoles 13 de noviembre de 2024, a las 4 p.m. ET. El evento se llevará a cabo de manera virtual y la dirección estará disponible para reuniones individuales con los asistentes registrados. Las partes interesadas pueden acceder a la transmisión en vivo a través de la sección 'Eventos y Presentaciones' en el sitio web de relaciones con inversores de Zevra en investors.zevra.com.
Zevra Therapeutics (NASDAQ: ZVRA)는 다가오는 Guggenheim Securities Healthcare Innovation Conference에 참여할 예정이라고 발표했습니다. 회사의 회장 겸 CEO인 Neil F. McFarlane은 2024년 11월 13일 수요일 오후 4시(ET)에 편안한 대화에 참여할 것입니다. 이 행사는 가상으로 개최되며, 경영진은 등록된 참석자와의 일대일 회의에 참여할 수 있습니다. 관심 있는 분들은 Zevra의 투자자 관계 웹사이트 investors.zevra.com의 '이벤트 및 프레젠테이션' 섹션을 통해 생중계에 접속할 수 있습니다.
Zevra Therapeutics (NASDAQ: ZVRA) a annoncé sa participation à la prochaine Guggenheim Securities Healthcare Innovation Conference. Le président et PDG de l'entreprise, Neil F. McFarlane, prendra part à une conversation informelle le mercredi 13 novembre 2024, à 16h00 ET. L'événement se déroulera virtuellement et la direction sera disponible pour des réunions individuelles avec les participants enregistrés. Les parties intéressées peuvent accéder à la diffusion en direct via la section 'Événements et présentations' sur le site de relations avec les investisseurs de Zevra à l'adresse investors.zevra.com.
Zevra Therapeutics (NASDAQ: ZVRA) hat seine Teilnahme an der bevorstehenden Guggenheim Securities Healthcare Innovation Conference angekündigt. Der Präsident und CEO des Unternehmens, Neil F. McFarlane, wird am Mittwoch, den 13. November 2024, um 16:00 Uhr ET an einem informellen Gespräch teilnehmen. Die Veranstaltung findet virtuell statt, und das Management steht für Einzelgespräche mit registrierten Teilnehmern zur Verfügung. Interessierte Parteien können über den Bereich 'Veranstaltungen und Präsentationen' auf der Investor-Relations-Website von Zevra unter investors.zevra.com auf den Live-Webcast zugreifen.
- None.
- None.
CELEBRATION, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will participate in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference Virtual on Wednesday, Nov. 13, 2024, at 4 p.m. ET. Additionally, management will be available for one-on-one meetings with registered attendees.
The live webcast will be accessible via “Events & Presentations” on the Investor Relations section of Zevra’s website at investors.zevra.com.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Expanded access programs are made available by Zevra Therapeutics, Inc. and its affiliates and are subject to the Company's Expanded Access Program (EAP) policy, as published on its website. Participation in these programs is subject to the laws and regulations of each jurisdiction under which each respective program is operated. Eligibility for participation in any such program is at the treating physician's discretion.
For more information, please visit www.zevra.com or follow us on X (formerly Twitter) and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra’s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended Dec. 31, 2023, Zevra’s Quarterly Report for the quarter ended June 30, 2024, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Zevra Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Russo Partners Contact
David Schull
+1 (858) 717-2310
david.schull@russopartnersllc.com
FAQ
When is Zevra Therapeutics (ZVRA) presenting at the Guggenheim Securities Healthcare Conference?
How can investors watch Zevra's (ZVRA) Guggenheim Conference presentation?
What type of presentation will Zevra (ZVRA) give at the Guggenheim Healthcare Conference?